Two doses of Pfizer vaccine offer limited protection, says Albert Bourla, Pfizer CEO.
Covid should now be treated as an endemic virus similar to flu, and ministers should end mass-vaccination after the booster campaign, the former chairman of the UK’s vaccine taskforce has said.
With health chiefs and senior Tories also lobbying for a post-pandemic plan for a straining NHS, Dr Clive Dix called for a major rethink of the UK’s Covid strategy, in effect reversing the approach of the last two years and returning to a “new normality”.
“We need to analyse whether we use the current booster campaign to ensure the vulnerable are protected, if this is seen to be necessary,” he said. “Mass population-based vaccination in the UK should now end.”
A leading Australian pharmacist says measures such as wearing masks and getting six-monthly Covid-19 vaccinations could be a reality for many years.
Trent Twomey, National President of the Pharmacy Guild, says if modelling shows that its best for people to get a Covid jab ‘every six months’, then Australians should do so.
He dismissed concerns over lingering vaccine hesitancy and wearing masks, saying Australians ‘just need to accept’ necessary measures because ‘it’s pretty simple’.
Dec 10 (Reuters) – Most of the 43 COVID-19 cases caused by the Omicron variant identified in the United States so far were in people who were fully vaccinated, and a third of them had received a booster dose, according to a U.S. report published on Friday.
The U.S. Centers for Disease Control and Prevention (CDC) said that of the 43 cases attributed to Omicron variant, 34 people had been fully vaccinated. Fourteen of them had also received a booster, although five of those cases occurred less than 14 days after the additional shot before full protection kicks in.
While the numbers are very small, they add to growing concerns that current COVID-19 vaccines may offer less protection against the highly transmissible new variant.
Millions of over-75s in England will miss out on routine health checks until April to free up GPs to help with the UK’s anti-Omicron booster drive.
Campaigners accused the Government of breaking its promises to boost face-to-face appointments and slammed the decision as a ‘self defeating exercise’, as over-75s will flood into A&E with their health problems.
The decision to suspend the health checks came from the Joint Committee on Vaccination and Immunisation (JCVI) in response to the Government’s mammoth effort to turbocharge the UK’s Covid booster to ward off Omicron.
The five most vaccinated states in the United States—Vermont, Rhode Island, Maine, Connecticut and Massachusetts—are all experiencing surges in new COVID-19 cases, as the Biden administration urges people over 50 to get their booster jabs.
Vermont, which is the most vaccinated state, with 73 percent of its population fully jabbed, saw an 18 percent rise in new daily COVID cases over the last 14 days before November 24, according to New York Times data.
On Thursday, the government published its 44th vaccine surveillance report and in a table on page 18 it noted 2,032 deaths of double-vaccinated individuals over 70. More than 3,000 from the same double-jabbed cohort were hospitalised.
Researchers who scoured the records of nearly 800,000 U.S. veterans found that in early March, just as the Delta variant was gaining a toehold across American communities, the three vaccines were roughly equal in their ability to prevent infections.
But over the next six months, that changed dramatically.
By the end of September, Moderna’s two-dose COVID-19 vaccine, measured as 89% effective in March, was only 58% effective.
Some parents are now questioning if Israel moved too fast in jabbing their children. And several health professionals and politicians are demanding the abolition of a policy expected to go into effect next month, which states that the Green Pass will be given only to those who receive a third dose of the vaccine six months after getting a second vaccination.
Professor Sucharit Bhakdi: “You are now witnessing the greatest crime that England has ever committed in its history.”
Vaccines typically do not outperform natural immunity, so it should come as no surprise that Covid vaccines do not offer long-term protection against infection. At the same time, we can be confident that they will continue to work well to prevent severe clinical outcomes. The role of these vaccines is to offer protection to the clinically vulnerable; to foist them upon those who are at negligible risk in the hope of augmenting herd immunity is illogical…
Will boosters achieve what two doses could not? For those who are extremely vulnerable and show no evidence of mounting a significant immune response after two doses, it is entirely reasonable to attempt a third dose.
But it can be to no-one else’s individual gain to submit to a third jab, having already reduced the risk of severe disease (which was very small in the first place for most) by receiving two inoculations. For there to be the collective benefit of herd immunity, the booster would have to provide life-long protection against infection – unless we are willing to accept repeated mass vaccination into the foreseeable future. Aside from being a colossal diversion of limited resources, that would open the door to a permanent state of lockdown as we lurch from one booster campaign to the next.
The real-world study includes data on positive Covid PCR test results between May and July 2021 among more than a million people who had received two doses of Pfizer or AstraZeneca vaccine.
Protection after two shots of Pfizer decreased from 88% at one month to 74% at five to six months.
For AstraZeneca, the fall was from 77% to 67% at four to five months.
I reiterate our call: “slow down and get the science right—there is no legitimate reason to hurry to grant a license to a coronavirus vaccine.”
FDA should be demanding that the companies complete the two year follow-up, as originally planned (even without a placebo group, much can still be learned about safety). They should demand adequate, controlled studies using patient outcomes in the now substantial population of people who have recovered from covid. And regulators should bolster public trust by helping ensure that everyone can access the underlying data.
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (<18% peak levels within 100 days of the 2nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.
Dr Bauer of the Francis Crick Institute explains that the Pfizer vaccine produces 5-6 times fewer neutralising antibodies that play a key role in protecting us from the Indian variant. He suggests that booster Pfizer jabs will be essential.
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.
The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn.
In the case of single-dose recipients, our data show that NAbTs are significantly lower against B.1.617.2 and B.1.351 VOCs relative to B.1.1.7, implying that although a single dose might still afford considerably more protection than no vaccination, single-dose recipients are likely to be less protected against these SARS-CoV-2 variants. These data therefore suggest that the benefits of delaying the second dose, in terms of wider population coverage and increased individual NAbTs after the second dose,7 must now be weighed against decreased efficacy in the short-term, in the context of the spread of B.1.617.2. Worldwide, our data highlight the ongoing need to increase vaccine supply to allow all countries to extend second-dose protection as quickly as possible.
In the longer term, we note that both increased age and time since the second dose of BNT162b2 significantly correlate with decreased NAb activity against B.1.617.2 and B.1.351—both of which are also characteristic of the population in the UK at highest risk of severe COVID-19 (ie, older and vaccinated earlier), independent of other existing factors such as compromised immune status or comorbidity, or geographic-specific responses to vaccination.